[Back to Issue 7 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]

REVIEW: Will Peptides Help to Stop COVID-19?

Viktoriya G. Krut’1, Sergei A. Chuvpilo1, Irina V. Astrakhantseva1, Liubov I. Kozlovskaya2,3, Grigory A. Efimov4, Andrei A. Kruglov5,6,7, Marina S. Drutskaya1,8, and Sergei A. Nedospasov1,5,6,8,a*

1Sirius University of Science and Technology, 354340 Federal Territory Sirius, Krasnodar Krai, Russia

2Chumakov Federal Scientific Center for Research and Development of Immunobiological Products, Russian Academy of Sciences, 108819 Moscow, Russia

3Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, 119991 Moscow, Russia

4National Medical Research Center of Hematology, Ministry of Health of the Russian Federation, 125167 Moscow, Russia

5Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119234 Moscow, Russia

6Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia

7German Rheumatism Research Center (DRFZ), Leibniz Institute, 10117 Berlin, Germany

8Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia

* To whom correspondence should be addressed.

Received December 31, 2021; Revised April 24, 2022; Accepted May 11, 2022
Peptides are widely used for the diagnostics, prevention, and therapy of certain human diseases. How useful can they be for the disease caused by the SARS-CoV-2 coronavirus? In this review, we discuss the possibility of using synthetic and recombinant peptides and polypeptides for prevention of COVID-19 via blocking the interaction between the virus and its main receptor ACE2, as well as components of antiviral vaccines, in particular, against new emerging virus variants.
KEY WORDS: SARS-CoV-2, ACE2, vaccine, T-cell epitopes

DOI: 10.1134/S0006297922070021